Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
about
Concentrated insulins: the new basal insulinsSafety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanPatient safety and minimizing risk with insulin administration - role of insulin degludecOptimal therapy of type 2 diabetes: a controversial challengeAchieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.Pursuit of a perfect insulin.Degludec: the new ultra-long insulin analogue.Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
P2860
Q26750438-03AF617D-669D-451B-B864-AB38C0254E19Q26778763-91A8E849-F8B0-4C25-B755-EEB60DDEBC79Q27025548-77C3EA02-DFE9-4CFB-948F-A1047C9BC9A0Q33577712-F29CA4CD-C7D2-4E0B-A9C4-7DFA1760B6DBQ34563587-66AD9AA3-599F-426C-B922-91C10FC187CAQ35457098-6D205039-B337-473F-86BA-6873FA4FF64FQ37432141-49D0BE4C-8860-4037-A4DC-EB945442AB52Q38284244-B9948013-CDD7-412F-8BF4-4EBE3CAE6F76Q38470334-BBE8E0BC-1860-4331-946C-4D8C36B20CEFQ38640170-918D5551-9903-4183-A824-77D89F1089AAQ38778988-989F8E9C-34D7-4134-A238-A0115EAD7B2FQ41564970-B2912BA4-B59A-446F-8320-59917D0F031BQ46358093-83921538-8334-40E2-A986-2DC666006B2D
P2860
Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Elderly patients with diabetes ...... analysis of phase IIIa trials.
@en
Elderly patients with diabetes ...... analysis of phase IIIa trials.
@nl
type
label
Elderly patients with diabetes ...... analysis of phase IIIa trials.
@en
Elderly patients with diabetes ...... analysis of phase IIIa trials.
@nl
prefLabel
Elderly patients with diabetes ...... analysis of phase IIIa trials.
@en
Elderly patients with diabetes ...... analysis of phase IIIa trials.
@nl
P2093
P2860
P1433
P1476
Elderly patients with diabetes ...... analysis of phase IIIa trials.
@en
P2093
Christopher Sorli
David Oyer
Henriette Mersebach
Mark Warren
Stephen C L Gough
Thue Johansen
P2860
P2888
P304
P356
10.1007/S40266-013-0128-2
P577
2013-12-01T00:00:00Z